Cardiovascular Critical Care I

N Engl J Med. 2009;361(11):1045-1057. https://doi.

org/10.1056/nejmoa0904327

Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh

KH. Antithrombotic and thrombolytic therapy for val-

vular disease: Antithrombotic Therapy and Prevention

of Thrombosis, 9th ed: American College of Chest

Physicians Evidence-Based Clinical Practice Guidelines.

Chest.

2012;141(2

suppl):e576S-e600S.

https://doi.

org/10.1378/chest.11-2305

Wijeyeratne

YD,

Heptinstall

S.

Anti-platelet

therapy: ADP receptor antagonists. Br J Clin

Pharmacol.

2011;72(4):647-657.

https://doi.

org/10.1111/j.1365-2125.2011.03999.x

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel

versus clopidogrel in patients with acute coronary syn-

dromes. N Engl J Med. 2007;357(20):2001-2015. https://

doi.org/10.1056/nejmoa0706482

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/

AHA/HFSA focused update of the 2013 ACCF/AHA

guideline for the management of heart failure: a report

of the American College of Cardiology/American

Heart Association Task Force on Clinical Practice

Guidelines and the Heart Failure Society of America.

Circulation.

2017;136(6):e137-e161.

https://doi.

org/10.1161/cir.0000000000000509

Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022

ESC guidelines for the management of patients with

ventricular arrhythmias and the prevention of sudden

cardiac death. Eur Heart J. 2022;43(40):3997-4126.

https://doi.org/10.1093/eurheartj/ehac262

Zimetbaum P. Antiarrhythmic drug therapy for atrial

fibrillation. Circulation. 2012;125(2):381-389. https://doi.

org/10.1161/circulationaha.111.019927